Developer docs
API playgroundTry for free, no card

Search company profiles

Libbs Farmacêutica

Full company profile

uuid0009txh

Namestring
Libbs Farmacêutica
Legal namestring
Libbs Farmacêutica Ltda
Websiteurl
libbs.com.br
Company typeenum
Private
Founded yearint
1958
Descriptiontext

Libbs Farmacêutica is a privately held, family-controlled Brazilian pharmaceutical company founded in 1958 and headquartered in São Paulo. It develops, manufactures and commercializes more than 100 pharmaceutical brands across 240 presentations, spanning eight therapeutic areas: cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, central nervous system and respiratory. The company's products reach 94,000+ pharmacies and drugstores across Brazil, with a field sales force visiting 86,000+ physicians in 1,175 cities; 13.5+ million patients were treated with Libbs products in 2025. The firm also operates the Biotec biotechnology platform in Embu das Artes, the first industrial-scale single-use bioreactor facility in Brazil, which produces domestic biosimilar monoclonal antibodies including rituximab, bevacizumab and trastuzumab.

The company's core technology base combines small-molecule pharmaceutical manufacturing at its 151,000 m² industrial complex in Embu das Artes with the Biotec biosimilar facility developed via technology partnership with Mabxience (Chemo) and supplemented by co-development arrangements with Biocon, Mylan and Polpharma Biologics. The Biotec Multipurpose Line extends the platform into mRNA development, CDMO services for external partners, and partnerships with universities and research institutes. In 2024 the company inaugurated the Planta Piloto Biotec for bioprocess scale-up and clinical material production, plus Brazil's first High-Potency Drug Factory for advanced oncology. Vertically integrated API production is anchored by subsidiary Libbs Farmoquímica Ltda (since 2006).

Libbs generates revenue primarily through one-time sales of pharmaceutical and biosimilar products via retail pharmacy distribution plus an institutional/hospital channel for oncology, augmented by CDMO services and exclusive distribution deals with multinational partners including Pfizer (palbociclib), Eli Lilly (galcanezumab) and Mithra Pharmaceuticals (drospirenone+estetrol oral contraceptive). The company reaches patients through retail pharmacy distribution, healthcare professional engagement, and content platforms A Vida Plena and Trate da Vida. R&D investment reached R$208.49 million in 2025, supporting in-house programs such as the Research Incentive Program (PIP) and open innovation program Linna. Pricing is not publicly disclosed and the company is privately held with no parent or institutional investor disclosed.

Short descriptiontext

Libbs Farmacêutica is a privately held Brazilian pharmaceutical company founded in 1958 that develops, manufactures, and commercializes over 100 pharmaceutical brands across eight therapeutic areas, including Brazil's first industrial-scale biosimilar monoclonal antibody facility, serving patients through 94,000+ pharmacies nationwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersSão Paulo, Brazil
HQ citystring
São Paulo
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, biosimilar medications, monoclonal antibody production, contract manufacturing services, specialty pharmaceutical products
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Products
TypeOne Time License
Description

Development, manufacturing and commercialization of prescription and OTC pharmaceutical products across multiple therapeutic areas including cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, CNS and respiratory.

libbs.com.br
2Biosimilar Medications
TypeOne Time License
Description

Production and commercialization of biological and biosimilar medications for complex diseases including cancer and autoimmune diseases. Includes rituximab, bevacizumab, trastuzumab and other monoclonal antibodies.

libbs.com.br
3CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing services for other pharmaceutical companies using the Biotec multipurpose platform.

libbs.com.br
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Libbs Farmacêutica develops, manufactures, and commercializes a portfolio of 100+ pharmaceutical brands across 240+ presentations in eight therapeutic areas, including cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, respiratory, and central nervous system conditions. The company operates Brazil's first industrial-scale single-use bioreactor platform (Biotec) producing biosimilar monoclonal antibodies such as rituximab, bevacizumab, and trastuzumab, and offers contract development and manufacturing (CDMO) services. Its products reach Brazilian patients through 94,000+ pharmacies and 86,000+ physician visits by a national field sales force.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 13.5+ million people treated with Libbs products
+3 more records
Product overview1 text field

Libbs Farmacêutica is a Brazilian pharmaceutical company with a diversified portfolio of over 100 brands across 240 presentations. The company operates across multiple therapeutic areas including Cardiometabólicos, Dermatológicos, Gástricos, Ginecológicos, Hematológicos, Oncológicos, Respiratórios, and Sistema Nervoso Central. Key products include biosimilar monoclonal antibodies (Trastuzumabe for breast cancer, Rituximabe for lymphoma/leukemia, Bevacizumabe for lung cancer), consumer health products (Maxidrate nasal gel, Muvinlax laxative), and an innovative oral contraceptive combining drospirenone with estetrol. The company operates through multiple platforms including Biotec for biologics manufacturing, open innovation program Linna, and internal AI assistant LIS. Products are supported by patient portal A Vida Plena and healthcare professional portal Trate da Vida.

Product and service8 records
1Trastuzumabe
CategoryBiosimilar / Oncology
Description

Biosimilar monoclonal antibody indicated for the treatment of metastatic breast cancer. First Trastuzumab biosimilar commercialized in Brazil, co-developed with Biocon and Mylan and brought exclusively to Brazil by Libbs.

2Rituximabe
CategoryBiosimilar / Oncology / Hematology
Description

Monoclonal antibody produced domestically for treatment of non-Hodgkin lymphoma and chronic lymphoid leukemia. First monoclonal antibody produced at industrial scale in Brazil using Libbs' Biotec single-use bioreactor platform.

3Bevacizumabe
CategoryBiosimilar / Oncology
Description

Monoclonal antibody biosimilar indicated for lung cancer treatment, produced via Libbs' Biotec single-use bioreactor platform.

4Muvinlax
CategoryConsumer Health / OTC Gastrointestinal
Description

Laxative medication for treatment of intestinal constipation symptoms, sold as an over-the-counter consumer health product through Brazilian retail pharmacies.

5Maxidrate
CategoryConsumer Health / OTC Respiratory
Description

Nasal hydration gel for children and adults, preventing nasal dryness. Contains exclusive Ringer Lactate formulation, free of preservatives and vasoconstrictors. Sold through Brazilian retail pharmacies as a consumer health product.

6Contraceptive with drospirenone and estetrol
CategoryPrescription Pharmaceutical / Women's Health
Description

Innovative combined oral contraceptive combining drospirenone with estetrol (E4), a natural-identical estrogen produced from plant sources. Marketed as the most innovative combined oral contraceptive in 15 years, offering greater safety with minimal endocrine, metabolic, and hemostatic impact. Partnered with Mithra Pharmaceuticals.

7Tarfic
CategoryPrescription Pharmaceutical / Dermatology
Description

Topical tacrolimus ointment for dermatological treatment, available in 0.3 mg/g and 1 mg/g presentations. Sold through Brazilian retail pharmacies as a prescription dermatological product.

8Linha Multipropósito Biotec (CDMO Services)
CategoryBiotechnology Contract Manufacturing Services
Description

Contract development and manufacturing (CDMO) service offering using Libbs' Biotec multipurpose biotech line. Provides bioprocess scale-up, biomolecule development, and clinical material production for other pharmaceutical companies, including capabilities in messenger RNA technology. Establishes partnerships with universities, research institutes, and startups.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-10
Description

Licensing agreement for a biosimilar for autoimmune diseases. Polpharma Biologics handles development and manufacturing while Libbs commercializes the product in Brazil. The biosimilar is under development and expected to seek approval within three years.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Exclusive distribution, promotion and commercialization agreement for Palbociclibe, oral medication for breast cancer treatment. ANVISA registration granted December 2023.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Exclusive distribution and commercialization partnership for Galcanezumabe medication for migraine treatment in Brazil.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Partnership for innovative oral contraceptive combining drospirenone with estetrol (E4). ANVISA approval received for commercialization in Brazil in 2023. Estetrol is a natural-identical estrogen produced during pregnancy extracted from plant sources.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Co-development partnership for Trastuzumab biosimilar for breast cancer treatment. Products codesigned by Biocon and Mylan, brought exclusively to Brazil by Libbs. First Trastuzumab biosimilar commercialized in Brazil in 2018.

6Bio-Manguinhos (Fiocruz)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Partnership for fill-finish of Yellow Fever vaccine distributed throughout Brazil as part of public health initiative.

libbs.com.br
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-01-01
Description

Technology transfer agreement for production of pharmaceutical ingredients Tacrolimo and Sirolimo, achieving 100% verticalization in Tacrolimo production.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

Partnership for production of biological medications. Established Biotec facility for biosimilar development with rituximab and bevacizumab as first products. Mabxience, the biotechnology arm of Chemo, provided technology transfer for single-use bioreactor platform.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Brazilian pharmaceutical manufacturer with strong presence in generics, anesthetics, oncology and hospital channel. Comparable to Libbs in oncology portfolio, API vertical integration and Brazilian institutional sales.

TypeDirect peer
Description

Brazil's largest pharmaceutical company by units sold, operating across branded generics, OTC and prescription pharma. Direct competitor to Libbs in Brazilian pharmacy retail with broader therapeutic coverage and larger manufacturing scale.

3Eurofarma
TypeDirect peer
Description

Brazilian multinational pharmaceutical company with operations across branded generics, prescription and biotech. Comparable to Libbs in therapeutic breadth, Brazilian market presence and growing biosimilar/biotech investments.

TypeDirect peer
Description

Brazilian pharmaceutical company with diversified portfolio across prescription, OTC and dermatology. Competes with Libbs in cardiology, CNS, gynecology and dermatology segments in the Brazilian retail channel.

TypeDirect peer
Description

Largest Brazilian pharma by revenue (formerly Hypermarcas), with broad OTC, prescription and branded generic portfolio. Directly comparable in retail pharmacy positioning, therapeutic breadth and Brazilian market scale.

TypeDirect peer
Description

Brazilian pharmaceutical company specializing in prescription drugs, dermatology and women's health. Competes with Libbs in dermatology, gynecology and CNS therapeutic areas within the Brazilian market.

TypeEmerging player
Description

Brazilian joint venture between Aché, EMS, Eurofarma and Hypera focused on biosimilars. Emerging direct competitor to Libbs's Biotec platform in monoclonal antibody biosimilars in Brazil, backed by the country's largest pharma players.

TypeEmerging player
Description

India-based biosimilar specialist (and existing Libbs partner for trastuzumab). Competes in the same global biosimilar molecules (rituximab, trastuzumab, bevacizumab) and represents both partner and competitive threat to Libbs.

TypeBroad incumbent
Description

South Korean biosimilar leader with commercialized monoclonal antibody biosimilars across oncology and autoimmune. As global biosimilar manufacturers expand into Latin America, Celltrion represents the most likely multinational competitor to Libbs's oncology biosimilar franchise.

TypeBroad incumbent
Description

Global pharma incumbent and existing Libbs partner (exclusive distribution of palbociclib). Competes with Libbs across oncology, cardiology and women's health while simultaneously serving as both collaborator and competitor in the Brazilian market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Libbs Farmacêutica

Pharmaceuticalslibbs.com.br

Libbs Farmacêutica is a privately held Brazilian pharmaceutical company founded in 1958 that develops, manufactures, and commercializes over 100 pharmaceutical brands across eight therapeutic areas, including Brazil's first industrial-scale biosimilar monoclonal antibody facility, serving patients through 94,000+ pharmacies nationwide.

What Libbs Farmacêutica does

Libbs Farmacêutica is a privately held, family-controlled Brazilian pharmaceutical company founded in 1958 and headquartered in São Paulo. It develops, manufactures and commercializes more than 100 pharmaceutical brands across 240 presentations, spanning eight therapeutic areas: cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, central nervous system and respiratory. The company's products reach 94,000+ pharmacies and drugstores across Brazil, with a field sales force visiting 86,000+ physicians in 1,175 cities; 13.5+ million patients were treated with Libbs products in 2025. The firm also operates the Biotec biotechnology platform in Embu das Artes, the first industrial-scale single-use bioreactor facility in Brazil, which produces domestic biosimilar monoclonal antibodies including rituximab, bevacizumab and trastuzumab.

The company's core technology base combines small-molecule pharmaceutical manufacturing at its 151,000 m² industrial complex in Embu das Artes with the Biotec biosimilar facility developed via technology partnership with Mabxience (Chemo) and supplemented by co-development arrangements with Biocon, Mylan and Polpharma Biologics. The Biotec Multipurpose Line extends the platform into mRNA development, CDMO services for external partners, and partnerships with universities and research institutes. In 2024 the company inaugurated the Planta Piloto Biotec for bioprocess scale-up and clinical material production, plus Brazil's first High-Potency Drug Factory for advanced oncology. Vertically integrated API production is anchored by subsidiary Libbs Farmoquímica Ltda (since 2006).

Libbs generates revenue primarily through one-time sales of pharmaceutical and biosimilar products via retail pharmacy distribution plus an institutional/hospital channel for oncology, augmented by CDMO services and exclusive distribution deals with multinational partners including Pfizer (palbociclib), Eli Lilly (galcanezumab) and Mithra Pharmaceuticals (drospirenone+estetrol oral contraceptive). The company reaches patients through retail pharmacy distribution, healthcare professional engagement, and content platforms A Vida Plena and Trate da Vida. R&D investment reached R$208.49 million in 2025, supporting in-house programs such as the Research Incentive Program (PIP) and open innovation program Linna. Pricing is not publicly disclosed and the company is privately held with no parent or institutional investor disclosed.

Libbs Farmacêutica firmographics

Firmographics
Name
Libbs Farmacêutica
Legal name
Libbs Farmacêutica Ltda
Website
https://libbs.com.br
Company type
Private
Founded year
1958
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Libbs Farmacêutica is a privately held Brazilian pharmaceutical company founded in 1958 that develops, manufactures, and commercializes over 100 pharmaceutical brands across eight therapeutic areas, including Brazil's first industrial-scale biosimilar monoclonal antibody facility, serving patients through 94,000+ pharmacies nationwide.
Ownership category
akta.pro rank

Libbs Farmacêutica industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Pharmaceutical manufacturing
  • Biosimilar medications
  • Monoclonal antibody production
  • Contract manufacturing services
  • Specialty pharmaceutical products

Where Libbs Farmacêutica is headquartered

Location

Headquarters

HQ city
São Paulo
HQ country
Brazil
HQ region
Latin America

Offices3 records

Markets served

Libbs Farmacêutica business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical Products: Development, manufacturing and commercialization of prescription and OTC pharmaceutical products across multiple therapeutic areas including cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, CNS and respiratory.
  2. Biosimilar Medications: Production and commercialization of biological and biosimilar medications for complex diseases including cancer and autoimmune diseases. Includes rituximab, bevacizumab, trastuzumab and other monoclonal antibodies.
  3. CDMO Services: Contract development and manufacturing services for other pharmaceutical companies using the Biotec multipurpose platform.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Libbs Farmacêutica product offering

Product offering

Core offering

Libbs Farmacêutica develops, manufactures, and commercializes a portfolio of 100+ pharmaceutical brands across 240+ presentations in eight therapeutic areas, including cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, respiratory, and central nervous system conditions. The company operates Brazil's first industrial-scale single-use bioreactor platform (Biotec) producing biosimilar monoclonal antibodies such as rituximab, bevacizumab, and trastuzumab, and offers contract development and manufacturing (CDMO) services. Its products reach Brazilian patients through 94,000+ pharmacies and 86,000+ physician visits by a national field sales force.

Product overview

Libbs Farmacêutica is a Brazilian pharmaceutical company with a diversified portfolio of over 100 brands across 240 presentations. The company operates across multiple therapeutic areas including Cardiometabólicos, Dermatológicos, Gástricos, Ginecológicos, Hematológicos, Oncológicos, Respiratórios, and Sistema Nervoso Central. Key products include biosimilar monoclonal antibodies (Trastuzumabe for breast cancer, Rituximabe for lymphoma/leukemia, Bevacizumabe for lung cancer), consumer health products (Maxidrate nasal gel, Muvinlax laxative), and an innovative oral contraceptive combining drospirenone with estetrol. The company operates through multiple platforms including Biotec for biologics manufacturing, open innovation program Linna, and internal AI assistant LIS. Products are supported by patient portal A Vida Plena and healthcare professional portal Trate da Vida.

Differentiator

Problem solved

Functional benefit

Products and services

  • Trastuzumabe Biosimilar monoclonal antibody indicated for the treatment of metastatic breast cancer. First Trastuzumab biosimilar commercialized in Brazil, co-developed with Biocon and Mylan and brought exclusively to Brazil by Libbs.
  • Rituximabe Monoclonal antibody produced domestically for treatment of non-Hodgkin lymphoma and chronic lymphoid leukemia. First monoclonal antibody produced at industrial scale in Brazil using Libbs' Biotec single-use bioreactor platform.
  • Bevacizumabe Monoclonal antibody biosimilar indicated for lung cancer treatment, produced via Libbs' Biotec single-use bioreactor platform.
  • Muvinlax Laxative medication for treatment of intestinal constipation symptoms, sold as an over-the-counter consumer health product through Brazilian retail pharmacies.
  • Maxidrate Nasal hydration gel for children and adults, preventing nasal dryness. Contains exclusive Ringer Lactate formulation, free of preservatives and vasoconstrictors. Sold through Brazilian retail pharmacies as a consumer health product.
  • Contraceptive with drospirenone and estetrol Innovative combined oral contraceptive combining drospirenone with estetrol (E4), a natural-identical estrogen produced from plant sources. Marketed as the most innovative combined oral contraceptive in 15 years, offering greater safety with minimal endocrine, metabolic, and hemostatic impact. Partnered with Mithra Pharmaceuticals.
  • Tarfic Topical tacrolimus ointment for dermatological treatment, available in 0.3 mg/g and 1 mg/g presentations. Sold through Brazilian retail pharmacies as a prescription dermatological product.
  • Linha Multipropósito Biotec (CDMO Services) Contract development and manufacturing (CDMO) service offering using Libbs' Biotec multipurpose biotech line. Provides bioprocess scale-up, biomolecule development, and clinical material production for other pharmaceutical companies, including capabilities in messenger RNA technology. Establishes partnerships with universities, research institutes, and startups.

Quantifiable outcome

  • 13.5+ million people treated with Libbs products
  • +3 more outcomes

Companies that use Libbs Farmacêutica

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles4 records

Libbs Farmacêutica technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Libbs Farmacêutica partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Polpharma BiologicscoreStrategic or Co-development Partner · 10 December 2025Licensing agreement for a biosimilar for autoimmune diseases. Polpharma Biologics handles development and manufacturing while Libbs commercializes the product in Brazil. The biosimilar is under development and expected to seek approval within three years.
  • PfizercoreChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive distribution, promotion and commercialization agreement for Palbociclibe, oral medication for breast cancer treatment. ANVISA registration granted December 2023.
  • Eli LillycoreChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive distribution and commercialization partnership for Galcanezumabe medication for migraine treatment in Brazil.
  • Mithra PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2023Partnership for innovative oral contraceptive combining drospirenone with estetrol (E4). ANVISA approval received for commercialization in Brazil in 2023. Estetrol is a natural-identical estrogen produced during pregnancy extracted from plant sources.
  • Biocon and MylancoreStrategic or Co-development Partner · 1 January 2018Co-development partnership for Trastuzumab biosimilar for breast cancer treatment. Products codesigned by Biocon and Mylan, brought exclusively to Brazil by Libbs. First Trastuzumab biosimilar commercialized in Brazil in 2018.
  • Bio-Manguinhos (Fiocruz)minorStrategic or Co-development Partner · 1 January 2017Partnership for fill-finish of Yellow Fever vaccine distributed throughout Brazil as part of public health initiative.
  • BioconcoreTechnology or Integration · 1 January 2016Technology transfer agreement for production of pharmaceutical ingredients Tacrolimo and Sirolimo, achieving 100% verticalization in Tacrolimo production.
  • Mabxience (Chemo)coreStrategic or Co-development Partner · 1 January 2013Partnership for production of biological medications. Established Biotec facility for biosimilar development with rituximab and bevacizumab as first products. Mabxience, the biotechnology arm of Chemo, provided technology transfer for single-use bioreactor platform.

Scale indicators10 records

Recent moves11 records

Expansion highlights6 records

Libbs Farmacêutica competitors and assessment

Company assessment

Direct peers

  • Cristália: Brazilian pharmaceutical manufacturer with strong presence in generics, anesthetics, oncology and hospital channel. Comparable to Libbs in oncology portfolio, API vertical integration and Brazilian institutional sales.
  • EMS Pharma: Brazil's largest pharmaceutical company by units sold, operating across branded generics, OTC and prescription pharma. Direct competitor to Libbs in Brazilian pharmacy retail with broader therapeutic coverage and larger manufacturing scale.
  • Eurofarma: Brazilian multinational pharmaceutical company with operations across branded generics, prescription and biotech. Comparable to Libbs in therapeutic breadth, Brazilian market presence and growing biosimilar/biotech investments.
  • Aché Laboratórios: Brazilian pharmaceutical company with diversified portfolio across prescription, OTC and dermatology. Competes with Libbs in cardiology, CNS, gynecology and dermatology segments in the Brazilian retail channel.
  • Hyper a Pharma: Largest Brazilian pharma by revenue (formerly Hypermarcas), with broad OTC, prescription and branded generic portfolio. Directly comparable in retail pharmacy positioning, therapeutic breadth and Brazilian market scale.
  • Biolab Farmacêutica: Brazilian pharmaceutical company specializing in prescription drugs, dermatology and women's health. Competes with Libbs in dermatology, gynecology and CNS therapeutic areas within the Brazilian market.

Emerging players

  • Bionovis: Brazilian joint venture between Aché, EMS, Eurofarma and Hypera focused on biosimilars. Emerging direct competitor to Libbs's Biotec platform in monoclonal antibody biosimilars in Brazil, backed by the country's largest pharma players.
  • Biocon Biologics: India-based biosimilar specialist (and existing Libbs partner for trastuzumab). Competes in the same global biosimilar molecules (rituximab, trastuzumab, bevacizumab) and represents both partner and competitive threat to Libbs.

Broad incumbents

  • Celltrion: South Korean biosimilar leader with commercialized monoclonal antibody biosimilars across oncology and autoimmune. As global biosimilar manufacturers expand into Latin America, Celltrion represents the most likely multinational competitor to Libbs's oncology biosimilar franchise.
  • Pfizer: Global pharma incumbent and existing Libbs partner (exclusive distribution of palbociclib). Competes with Libbs across oncology, cardiology and women's health while simultaneously serving as both collaborator and competitor in the Brazilian market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Libbs Farmacêutica compliance and trust

Trust signal

Compliance8 records

Libbs Farmacêutica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Libbs Farmacêutica leadership team

Management profile

Number of profiles

Profiles3 records

Libbs Farmacêutica subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Libbs Farmacêutica funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Libbs Farmacêutica M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Libbs Farmacêutica

What does Libbs Farmacêutica do?

Libbs Farmacêutica develops, manufactures, and commercializes a portfolio of 100+ pharmaceutical brands across 240+ presentations in eight therapeutic areas, including cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, respiratory, and central nervous system conditions. The company operates Brazil's first industrial-scale single-use bioreactor platform (Biotec) producing biosimilar monoclonal antibodies such as rituximab, bevacizumab, and trastuzumab, and offers contract development and manufacturing (CDMO) services. Its products reach Brazilian patients through 94,000+ pharmacies and 86,000+ physician visits by a national field sales force.

Is Libbs Farmacêutica a public or private company?

Libbs Farmacêutica is a private company. It is classified as family owned and is currently operating.

When was Libbs Farmacêutica founded?

Libbs Farmacêutica was founded in 1958. It employs 5,001 to 10,000 people.

Where is Libbs Farmacêutica based?

Libbs Farmacêutica is headquartered in São Paulo, Brazil, in the Latin America region.

How does Libbs Farmacêutica make money?

Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are biosimilar Medications and CDMO Services.

Who are Libbs Farmacêutica's main competitors?

Direct peers on record are Cristália, EMS Pharma, Eurofarma, Aché Laboratórios, Hyper a Pharma and Biolab Farmacêutica. Emerging players are Bionovis and Biocon Biologics. Broad incumbents are Celltrion and Pfizer.

Does Libbs Farmacêutica have an API?

No public API is recorded for Libbs Farmacêutica.

What industry is Libbs Farmacêutica in?

Libbs Farmacêutica's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWirePolpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune DiseasesPolpharma Biologics and Libbs Farmacêutica signed a licensing agreement giving Libbs exclusive rights to commercialize a biosimilar for autoimmune diseases in Brazil. Polpharma retains development and manufacturing responsibility, with the biosimilar expected to be submitted to Anvisa for approval within three years.PharmiWeb.comPolpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune DiseasesPolpharma Biologics, a Swiss biopharmaceutical company specializing in biosimilars, has signed a licensing agreement with Brazilian company Libbs Farmacêutica granting exclusive rights to commercialize a biosimilar for autoimmune diseases in Brazil. Polpharma Biologics retains full responsibility for development and manufacturing, while Libbs Farmacêutica will handle commercialization, marketing, and distribution in the Brazilian market. The biosimilar is currently under development and is expected to be submitted to Brazil's health regulatory agency (Anvisa) for approval within three years.Business Wire BlogPolpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune DiseasesPolpharma Biologics, a Swiss biopharmaceutical company specializing in biosimilars, has signed a licensing agreement with Brazilian company Libbs Farmacêutica granting exclusive rights to commercialize a biosimilar for autoimmune diseases in Brazil. Polpharma Biologics retains full responsibility for development and manufacturing while Libbs Farmacêutica will handle commercialization, marketing, and distribution in the Brazilian market. The biosimilar is currently under development and expected to be submitted to Brazil's health regulatory authority (Anvisa) for approval within three years.YourStoryBiocon partners with Libbs Farmaceutica to launch generic formulations in BrazilBiocon Pharma partnered with Brazil-based Libbs Farmaceutica to launch generic formulations in Brazil, marking its entry into Latin America. The out-licensing deal assigns Biocon Pharma drug development and manufacturing, while Libbs handles import, distribution, and marketing. The partnership builds on a 2017 biosimilar Trastuzumab collaboration.